In-vivo data to the highest technical and scientific standards
Scantox is the leading Nordic preclinical GLP accredited CRO – Contract Research Organization.
Based on decades of experience we are a trusted partner for in-vivo preclinical research services for the pharmaceutical and medical device industries. The Scantox services enable clients to progress their drug or device development based on consistent, high-quality solid data to the highest technical and scientific standards.
Scantox Services
Our main focus is on pharmacology and regulatory toxicology and based on decades of experience, we are a trusted partner for product development services within the pharmaceutical and medical device industries.
Our services span from handling and formulating test items over in-life studies to histopathology producing tissue slides for reviewing by our experienced team of pathologists.
Furthermore, we offer all standard clinical pathology analysis as well as specialized biomarkers that are required according to international toxicology guidelines. Dose formulation analysis, bioanalysis as well as safety pharmacology testing are also part of our core capabilities.
Upcoming Events
Latest News
Scantox acquires QPS Austria’s Neuropharmacology Division
30th November 2023 -- Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery Contract...
Scantox continues its growth journey with the acquisition of Solural Pharma
Scantox A/S (“Scantox”) announces the acquisition of Solural Pharma (“Solural”) in Denmark. Scantox is the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo. Solural has strong...
Scantox appoints Morten Fjordholt as Sr. Business Development Director
November 8th – Scantox Group, a leading provider of nonclinical services in Europe, has named Morten Fjordholt as Sr. Business Development Director with the overall responsibility of growing sales within toxicology and lab services and fostering positive relationships...
Careers
Join our team of professionals
We are continuously looking for new talents to join our teams in Denmark and Sweden.
Scientific Excellence
With over 20 years of extensive experience, we are considered global leaders within minipig toxicology studies, with studies conducted in Göttingen Minipigs.
We work to the highest scientific standards, and engage with partners in scientific collaborations to provide the best scientific results and highest degree of knowledge.
Scantox is a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, and a world leader in scientific research based on Göttingen Minipigs.
The Scantox Name
The Scantox name dates back to 1977. It holds the story of our geographic origination – SCANdinavia – and of our original key area of expertise – TOXicology.
Today Scantox is an international corporation, and our areas of expertise have expanded into a vast portfolio of preclinical study types. But our roots and values remain.
We are Scantox.
Our Mission
The Scantox team is passionate about our common mission to improve the health of people, by creating life-changing scientific results. Every day.
Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo.
Contact us for further information: +45 5686 1500
Contact us for further information: +45 5686 1500
About Scantox Group
Scantox is the leading Nordic preclinical GLP-accredited Contract Research Organization, focused on pharmacology and regulatory toxicology. We are headquartered in Denmark, in the same location as where the company was originally founded in 1977. In addition Scantox has several subsidiaries in Sweden.
Scantox is specialized in preclinical contract research services. Our scientific work enables pharmaceutical and biotechnology companies to progress drug development projects, based on solid high-quality data. Core competencies within the Scantox Group include Explorative and efficacy studies, PK-studies, general toxicology studies including Juvenile & EFD, local tolerance studies, wound healing studies and vaccines. GLP and GMP compliant. Scantox’ core business is studies within the Preclinical phase, but we also extend our expertise into studies in early discovery as well as preclinical tests that overlap into phases 1 and 2.
As one of the most experienced preclinical service providers, our in-vivo work is backed by decades of experience. This makes Scantox a highly trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, and a globally recognized leader for our expertise and long experience with the Göttingen Minipig. Our services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards.
Scantox is today owned by Impilo, the leading Nordic healthcare investment company.
